Alnes Pharma India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 4 Year, 1 Day
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.50 M
- Revenue Growth 156.51%
- Profit Growth 146.73%
- Ebitda 211.27%
- Net Worth 49.64%
- Total Assets 233.57%
About Alnes Pharma India
Alnes Pharma India Private Limited (APIPL) is a Private Limited Indian Non-Government Company incorporated in India on 24 February 2021 (Four years 1 days old ). Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹5.50 M.
Suresha Eranna, Negalaguli Aravinda, and Ademane Prabhavati serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U33100KA2021PTC144543
- Company No.
144543
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Feb 2021
- Date of AGM
24 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Alnes Pharma India?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suresha Eranna  | Director | 24-Feb-2021 | Current |
| Negalaguli Aravinda | Director | 24-Feb-2021 | Current |
| Ademane Prabhavati | Director | 24-Feb-2021 | Current |
Financial Performance of Alnes Pharma India.
Alnes Pharma India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 156.51% increase. The company also saw a substantial improvement in profitability, with a 146.73% increase in profit. The company's net worth Soared by an impressive increase of 49.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Alnes Pharma India?
Unlock access to Alnes Pharma India's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Amrutha Diagnostic Centre India Private LimitedSuresha Eranna is a mutual person
Charges (Loans)
₹5.50 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.55 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 Aug 2024 | Others | ₹4.50 M | Open |
| 12 May 2022 | Others | ₹1.00 M | Open |
How Many Employees Work at Alnes Pharma India?
Unlock and access historical data on people associated with Alnes Pharma India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Alnes Pharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Alnes Pharma India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.